[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,230
Citations 0
Correction
October 2018

Missing Conflict of Interest Disclosure

JAMA Oncol. 2018;4(10):1439. doi:10.1001/jamaoncol.2018.4091

In a number of articles published in JAMA Oncology,1-7 conflict of interest disclosures were not reported completely by Vinay Prasad, MD, MPH. Dr Prasad has written a letter to the journal8 explaining this inconsistent reporting of potential conflict of interest disclosures. All articles have been corrected online.

References
1.
Hernandez  I, Prasad  V, Gellad  WF.  Total costs of chimeric antigen receptor T-cell immunotherapy  [published online April 26, 2018].  JAMA Oncol. 2018;4(7):994-996. doi:10.1001/jamaoncol.2018.0977PubMedGoogle ScholarCrossref
2.
Marquart  J, Chen  EY, Prasad  V.  Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology  [published online April 17, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.1660PubMedGoogle Scholar
3.
Mailankody  S, Prasad  V.  Overall survival vs disease-specific survival—reply.  JAMA Oncol. 2018;4(4):586-587. doi:10.1001/jamaoncol.2017.3865PubMedGoogle ScholarCrossref
4.
Prasad  V, Kaestner  V, Mailankody  S.  Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers.  JAMA Oncol. 2018;4(2):157-158. doi:10.1001/jamaoncol.2017.4182PubMedGoogle ScholarCrossref
5.
Gyawali  B, Prasad  V.  Pemetrexed in nonsquamous non–small-cell lung cancer: the billion dollar subgroup analysis.  JAMA Oncol. 2018;4(1):17-18. doi:10.1001/jamaoncol.2017.1944PubMedGoogle ScholarCrossref
6.
Prasad  V.  Overestimating the benefit of cancer drugs.  JAMA Oncol. 2017;3(12):1737-1738. doi:10.1001/jamaoncol.2017.0107PubMedGoogle ScholarCrossref
7.
Beer  TM, Prasad  V.  Is “do everything!” always appropriate?—reply.  JAMA Oncol. 2017;3(11):1588-1589. doi:10.1001/jamaoncol.2017.2349PubMedGoogle ScholarCrossref
8.
Prasad  V.  Inconsistent reporting of potential conflicts of interest  [published online August 16, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.3461Google Scholar
×